Medical Management of Hair Loss: Finasteride, Minoxidil and Beyond
On this page
- Diagnose and classify before anything is prescribed
- Finasteride: the stabiliser with the strongest male evidence
- Minoxidil: the growth stimulant both sexes can use
- The second line: dutasteride, spironolactone and combinations
- Where PRP and mesotherapy fit
- Sequencing medical therapy around surgery
- Running medical management as a clinic service line
- Sources and further reading
Androgenetic alopecia is progressive. A transplant relocates hair; it does nothing to protect the native hair around the grafts, and in a patient whose loss is still moving, today's dense result becomes tomorrow's isolated frontal island. That is why medical management of hair loss is not a sideline for a surgical clinic. It is the mechanism that keeps surgical results looking intended five years on, the holding strategy for patients who are not yet candidates, and the source of long-term patient relationships that surgery alone cannot generate.
This overview covers the pharmacological toolkit as mainstream practice currently stands: finasteride, minoxidil in both forms, dutasteride, the anti-androgens used in female pattern loss, and where injectable adjuncts fit around them. It is written clinician-to-clinician, for doctors and clinic operators building or auditing a medical hair loss treatment service. It is not dosing guidance for patients.
Diagnose and classify before anything is prescribed
Medical management starts with confirming that the diagnosis really is androgenetic alopecia. In men the pattern is usually obvious and is staged on the Norwood scale, which remains the shared vocabulary for describing male pattern loss and anticipating progression. In women the picture is less reliable. Diffuse thinning graded on the Ludwig scale can be mimicked by telogen effluvium, thyroid dysfunction, iron deficiency and early scarring alopecias, and each of those has a different treatment and a different prognosis.
The minimum baseline for a credible service is short: a history covering duration, tempo and triggers; trichoscopy to document miniaturisation; targeted blood work where the history suggests it; and standardised photography under fixed lighting and angles. Photography is not administrative decoration. Response to every agent below is judged over months, and without baseline images neither the clinician nor the patient can distinguish stabilisation from drift.
Finasteride: the stabiliser with the strongest male evidence
Finasteride inhibits type II 5-alpha-reductase and lowers dihydrotestosterone, the androgen driving follicular miniaturisation in genetically susceptible scalp. The pivotal randomised trials in men with androgenetic alopecia, reported by Kaufman and colleagues, showed improved hair counts and slowed loss against placebo, with benefit maintained on continued treatment. For men it remains the backbone of medical treatment for a simple reason: it acts on the cause of progression rather than stimulating growth downstream of it.
The counselling burden is real and has grown. Sexual adverse effects were reported by a small minority of trial participants. A subset of patients report symptoms persisting after discontinuation; that phenomenon remains contested in the literature, but it must be covered in consent regardless of where the prescriber stands on it. Finasteride is not used in women of childbearing potential because of teratogenic risk to a male foetus. Document the discussion, give the patient time to decide, and never bury it inside a surgical consent form.
Minoxidil: the growth stimulant both sexes can use
Topical minoxidil is licensed over the counter in most markets in 2% and 5% preparations. Its mechanism is still incompletely understood, but practically it works independently of the androgen pathway, which makes it usable in male and female pattern loss alike and a natural partner to finasteride in men. Its weaknesses are operational. Twice-daily application erodes adherence, and the temporary shedding that can accompany the first weeks of use will be read as failure by any patient who was not warned about it in advance.
Low-dose oral minoxidil has moved rapidly from niche to common in hair clinics. It is off-label for hair loss everywhere, and clinicians using it need a working protocol for screening and follow-up, particularly around hypertrichosis, fluid retention and cardiovascular history. The evidence base is growing but remains thinner than for the licensed topical form. Present it to patients as what it is: a widely used off-label option, not a licensed standard.
The second line: dutasteride, spironolactone and combinations
Dutasteride inhibits both isoforms of 5-alpha-reductase and suppresses dihydrotestosterone more completely than finasteride. It is licensed for androgenetic alopecia in a small number of markets and prescribed off-label in most others; many clinics position it as an escalation for men progressing on finasteride. Spironolactone, an androgen receptor antagonist, is a mainstream off-label choice in female pattern loss, with the usual caveats around contraception and monitoring. Topical finasteride and compounded combination formulations are an active area with a thinner evidence base; treat them as emerging rather than established.
| Agent | Mechanism | Licensing for hair loss | Typical role |
|---|---|---|---|
| Finasteride (oral) | Type II 5-alpha-reductase inhibitor | Licensed for male androgenetic alopecia | First-line stabiliser in men |
| Minoxidil (topical 2% / 5%) | Growth stimulant, androgen-independent | Licensed, over the counter in most markets | First-line in men and women |
| Minoxidil (low-dose oral) | As topical, delivered systemically | Off-label everywhere | Alternative where adherence to topical fails |
| Dutasteride (oral) | Dual 5-alpha-reductase inhibitor | Licensed in a few markets, off-label elsewhere | Escalation in men progressing on finasteride |
| Spironolactone (oral) | Androgen receptor antagonist | Off-label | Female pattern loss, with monitoring |
Most patients who stay in treatment end up on combinations, typically a stabiliser plus a stimulant. The combination logic is complementary mechanisms, not stacking for its own sake.
Where PRP and mesotherapy fit
Injectable adjuncts occupy the space between drugs and surgery. Platelet-rich plasma has randomised, placebo-controlled evidence of improved hair density in androgenetic alopecia, including the trial reported by Gentile and colleagues, though preparation methods and injection schedules vary so widely between clinics that results are hard to generalise. Mesotherapy has a weaker and more heterogeneous evidence base and should be framed to patients accordingly. Neither replaces finasteride or minoxidil. Both are reasonable additions for patients who want more than pharmacology, or who cannot tolerate first-line agents.
For clinics, the operational questions matter more than the marketing ones: a written PRP protocol, honest comparative framing of PRP versus mesotherapy, and a properly structured PRP programme with consistent preparation and documented outcomes.
Sequencing medical therapy around surgery
For surgical clinics the sequencing question comes up daily, and mainstream practice runs in one direction: stabilise first, operate second, continue after. A man in his early twenties with an aggressive tempo and an immature pattern is a medical patient this year, whatever he came in asking for. Operating on him without stabilisation commits a finite donor supply to a moving target. For established surgical candidates, ongoing medical therapy protects the native hair between and around grafts, which is often what separates a natural five-year result from a transplanted island.
Whether minoxidil around the operative period reduces post-operative shock loss is debated; practice varies and the evidence is not definitive. What is not debated is that a patient whose progression goes untreated will want more surgery, sooner, with less donor hair available to deliver it.
Running medical management as a clinic service line
The service fails, clinically and commercially, when it is improvised. It works when it carries the same operational discipline as the surgical side: a named prescriber, written consent templates covering off-label use, a defined review schedule with photography, and escalation rules for non-responders. Fold those into the clinic's standard operating procedures rather than leaving them in one doctor's head.
Handled this way, medical management also changes the shape of the consultation. Patients who are refused surgery but offered a credible medical plan tend to stay with the clinic, and many become surgical patients later, at the right time; we cover that dynamic in consultation conversion. The clinics that do this well are not selling drugs. They are managing a chronic condition, and being paid for the management.
Sources and further reading
- Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Journal of the American Academy of Dermatology. 1998;39(4 Pt 1):578–589.
- Norwood OT. Male pattern baldness: classification and incidence. Southern Medical Journal. 1975;68(11):1359–1365.
- Gentile P, Garcovich S, Bielli A, et al. The effect of platelet-rich plasma in hair regrowth: a randomized placebo-controlled trial. Stem Cells Translational Medicine. 2015;4(11):1317–1323.
Frequently asked questions
What is medical management hair loss?
Medical management of hair loss is the use of licensed and off-label drugs to slow, stop or partially reverse androgenetic alopecia rather than, or alongside, surgery. The core agents are finasteride and topical minoxidil in men, and minoxidil with anti-androgens such as spironolactone in women. It also covers diagnosis, exclusion of non-androgenetic causes, baseline photography and structured follow-up, because response can only be judged over months.
Who is medical management hair loss for?
Almost every androgenetic alopecia patient. Early-stage patients who are not yet surgical candidates, surgical patients who need native hair protected around their grafts, young patients whose pattern is still declaring itself, and women with diffuse thinning for whom surgery is often unsuitable. The main exceptions are patients with contraindications to specific agents and those with non-androgenetic diagnoses, who need treatment of the underlying cause instead.
How long does the medical management hair loss process take?
It is open-ended. Hair cycles are slow, so a fair trial of any agent is generally six to twelve months before judging response, with standardised photographs at baseline and at reviews. Benefits are maintained only while treatment continues; stopping finasteride or minoxidil is typically followed by a gradual return to the untreated trajectory within months. Patients should understand from the first consultation that this is long-term therapy, not a course.
What does medical management hair loss cost?
Generic finasteride and minoxidil are inexpensive in most markets, which is why the service is often underweighted commercially. The real cost drivers for a clinic are consultation time, follow-up reviews and photography, not the drugs. Pricing varies widely by market; many clinics bundle medical management into transplant packages or run it as a review-based programme. Injectable adjuncts such as PRP sit at a different price point entirely.
What are the most common mistakes around medical management hair loss?
Prescribing without a diagnosis, especially in women, where telogen effluvium and scarring alopecias mimic pattern loss. Skipping baseline photography, which makes response unjudgeable. Failing to counsel on the initial shedding phase with minoxidil, which drives early discontinuation. Operating on young patients without stabilising them first. And presenting off-label options such as oral minoxidil as routine without documenting the discussion.
How do I evaluate a provider for medical management hair loss?
Look for a documented pathway: diagnosis and trichoscopy before prescription, written consent covering off-label use and adverse effects, standardised photography, and scheduled reviews at realistic intervals. Ask how they handle non-responders and when they escalate to second-line agents or adjuncts. A provider who promises visible regrowth within weeks, or who prescribes identically for every patient, is running a dispensary rather than a service.
The Hair Transplant Source editorial team produces independent, technique-level reference material for hair restoration clinicians and clinic operators. Articles are written by the team and, where the topic is clinical, reviewed by a named hair restoration surgeon before they are presented as reviewed clinical content.
- Independent editorial line
- Clinical articles reviewed by named surgeons
- No paid editorial coverage
Dr. Serkan Aygün is a hair restoration surgeon practising in Istanbul, with a surgical caseload in the 1,500–4,000 procedure range across FUE, DHI and Sapphire FUE techniques. He contributes clinical perspectives to Hair Transplant Source: content carrying his byline has been written or clinically approved by him before publication.
- Hair restoration surgeon — Istanbul
- 1,500+ FUE, DHI and Sapphire FUE procedures
- Contributing author & reviewer, Hair Transplant Source
Related reading
